RE: DHSC or not18 Jun 2021 16:05
Also,
from the BMJ
Sheila Bird, former programme leader at the MRC Biostatistics Unit, University of Cambridge, said, “The MHRA may need some time to tackle fully the plethora of study design, regulatory, and transparency problems raised by the FDA. Needing some time may explain why the MHRA accorded the Department of Health and Social Care an interim two month extension and has yet to make public the basis for its interim judgement.”
She said that the MHRA’s transparency failures, including that it has not provided details on how the recent review was carried out or its findings, must be immediately redressed.